Yes, Start Suboxone Now for Delayed Opioid Withdrawal
This patient is experiencing clear opioid withdrawal symptoms and should be inducted onto buprenorphine/naloxone (Suboxone) immediately, as she is an ideal candidate: she has completed detox from fentanyl, is showing objective withdrawal signs, and has opioid use disorder requiring medication-assisted treatment.
Why Suboxone is Appropriate Here
This patient presents with classic opioid withdrawal symptoms (myalgias, yawning, red eyes) after detoxification from fentanyl and oxycodone. The duloxetine 90 mg she's taking for chronic low back pain and depression does not treat opioid use disorder and will not prevent relapse. Buprenorphine/naloxone is the evidence-based treatment for opioid use disorder that simultaneously addresses her chronic pain and prevents return to illicit opioid use 1.
The key advantage here: she's already past the acute fentanyl withdrawal phase (having completed detox), so you can avoid the most dangerous precipitated withdrawal scenario. Her current delayed withdrawal from residual opioid exposure makes this the optimal window for induction.
Specific Induction Protocol
Start with buprenorphine-only (Subutex) for induction, then switch to Suboxone:
Day 1: Give 8 mg buprenorphine (Subutex) sublingually when objective withdrawal signs are present (which they already are). The FDA label specifically states induction should occur "when objective and clear signs of withdrawal are evident" 1.
Day 2: Give 16 mg buprenorphine (Subutex) sublingually 1.
Day 3 onward: Switch to Suboxone (buprenorphine/naloxone) at 16 mg daily. This is the FDA-recommended target maintenance dose 1.
Critical timing consideration: Since she's experiencing withdrawal from oxycodone (a short-acting opioid), you should administer the first dose immediately—she's already showing the required withdrawal signs. Do not wait longer 1.
Why Use Subutex First, Then Suboxone
The FDA label is explicit: "SUBUTEX contains no naloxone and is preferred for use during induction" 1. This prevents precipitated withdrawal during the vulnerable induction phase. After stabilization on days 1-2, switch to Suboxone because "due to the presence of naloxone, [it] is preferred when clinical use includes unsupervised administration" 1—which applies to rehab and outpatient settings.
Dosing Adjustments
The target is 16 mg/day, but adjust in 2-4 mg increments based on withdrawal suppression and cravings 1. The effective range is 4-24 mg/day, though most patients stabilize at 12-16 mg 1. Achieve adequate dosing rapidly—gradual titration over many days increases dropout risk 1.
Managing Her Chronic Pain
Here's where clinical judgment matters: Continue the duloxetine 90 mg—it provides both antidepressant effects and analgesic benefits for her chronic low back pain. Buprenorphine itself has analgesic properties and will help manage her pain 2. Recent consensus guidelines emphasize that buprenorphine should be continued for patients with both pain and opioid use disorder, as discontinuation destabilizes recovery 2.
If pain remains inadequate on buprenorphine alone, you can add non-opioid adjuncts (NSAIDs, gabapentinoids, physical therapy) rather than full mu-agonist opioids, given her opioid use disorder 2.
Critical Pitfalls to Avoid
Don't use Suboxone for initial induction—the naloxone component can precipitate severe withdrawal. Use Subutex first 1.
Don't delay induction waiting for "more severe" withdrawal—she already has objective signs. Delaying risks her leaving treatment or relapsing 1.
Don't underdose—studies show 16 mg is more effective than lower doses for retention and preventing relapse 1. Inadequate dosing is a major cause of treatment failure.
Don't abruptly stop duloxetine—it's managing her depression and pain. Buprenorphine addresses the opioid use disorder, not these comorbidities.
Screen for depression severity—depressive symptoms are the strongest predictor of dropout and relapse during opioid withdrawal 3. Her depression is already being treated, which is protective, but monitor closely.
Long-term Considerations
Plan for indefinite maintenance treatment, not short-term detox. The evidence strongly supports long-term buprenorphine maintenance for opioid use disorder—discontinuation leads to high relapse rates 2, 4. In the rehab setting, coordinate with her outpatient provider to ensure continuity when she transitions out.
The combination of buprenorphine for opioid use disorder plus duloxetine for pain and depression represents integrated care for her multiple conditions 5. This approach addresses the root cause (opioid use disorder) while managing comorbid chronic pain and depression simultaneously.